Priovant Therapeutics
NC - DurhamBiotechnology
Focus: Priovant Therapeutics is a Durham, NC-based autoimmune-focused biotechnology company developing oral JAK inhibitor therapies targeting rare and inflammatory conditions. The company operates as a clinical-stage biotech with a concentrated pipeline in immunology.
Profile data last refreshed 16h ago · AI intelligence enriched 1w ago
Open Jobs
2
Should You Work at Priovant Therapeutics?
AI assessmentBest suited for clinical development or operations professionals seeking hands-on Phase 2/3 execution experience in a specialized immunology setting; higher risk for career stability given opaque financials.
Why Work Here
- Focused pipeline with two Phase 3 programs (Brepocitinib in posterior uveitis and dermatomyositis) offering near-term catalysts and clinical advancement opportunities.
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Oral Brepocitinib
Cutaneous SarcoidosisClinical Trials (2)
NCT07532603A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Phase 2/3Help build intelligence for Priovant Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.